Neuromodulation of long-term sequelae of ischemic acute kidney injury
缺血性急性肾损伤长期后遗症的神经调节
基本信息
- 批准号:10410562
- 负责人:
- 金额:$ 45.43万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-01-01 至 2023-12-31
- 项目状态:已结题
- 来源:
- 关键词:AblationAcute Renal Failure with Renal Papillary NecrosisAdrenergic ReceptorAdultAffectAngiotensin IIAngiotensinogenApoptoticBehaviorBlood PressureBone MarrowCellsCharacteristicsChronic Kidney FailureClinicalCyclic AMP-Responsive DNA-Binding ProteinDataDenervationDevelopmentDiseaseDisease ProgressionDisease modelEnd stage renal failureEventExperimental ModelsFibroblastsFibrosisGeneticGoalsHealth Care CostsHeartHumanInfiltrationInflammationInflammatoryInformation SystemsInjuryInjury to KidneyKidneyKnockout MiceKnowledgeLeadLiverLungMediatingMedicalModelingNephrectomyNerveNorepinephrineOrganPathogenicityPathway interactionsPharmacologyPhenotypePlayPopulationProcessPublishingRENBP geneReceptors, Adrenergic, alpha-2ReninReperfusion InjuryRiskRoleSchemeSignal PathwaySignal TransductionSignaling MoleculeTestingTherapeuticTissuesTransforming Growth Factor betaTubular formationUreteral obstructionUridinebasecombinatorialcytokineeffective therapyefficacious treatmentfibrogenesisgenetic approachin vitro Modelin vivoinhibitorinnovationinterstitialkidney cellkidney fibrosislong-term sequelaemacrophagemouse modelneuroregulationnovelpreventprotein activationrecruitsingle moleculestandard of caretranscriptomicstranslational potential
项目摘要
Project Summary
Acute kidney injury (AKI) is recognized as a major risk for progressive chronic kidney disease (CKD). However, the
mechanism by which AKI leads to fibrogenesis and ultimately to end-stage renal disease (ESRD)2 is not well defined, Due
to limited knowledge of the primary signals that drive fibrogenesis, effective therapy for CKD is a major unmet medical
need. Our data indicate the novel paradigm that renal denervation can prevent renal fibrosis and inflammation in three
renal fibrogenesis models: 5/6 nephrectomy (5/6Nx), unilateral ureteral obstruction (UUO) and ischemic renal injury (IRI).
Our data indicate that the renal nerve-derived factor, norepinephrine (NE), signaling via α2-adrenergic receptor (α2-AR)
plays a key role in initiating fibrogenesis and inflammation and its inhibition pre-or post-injury can reduce fibrosis by about
70% in these CKD models. This finding is striking, as most experimental strategies targeting a single molecule or a pathway
rarely achieve a reduction of fibrosis of more than 50%. Our overall goal of this study is to delineate the mechanisms by
which NE signaling via α2-AR induces fibrosis and determine the therapeutic potential of inhibition of the α2-AR subtype
or its downstream signaling pathways in preventing renal fibrogenesis and inflammation in the IRI model. Our preliminary
studies indicate that NE signaling via α2-AR induces the expression of angiotensinogen (AGT) in renal proximal tubular cell
(RPTC) via activation of cAMP-response element-binding protein (CREB). Further, simultaneous inhibition of α2AR
subtypes A and C additively protected from inflammation and fibrosis, suggesting activation of subtype specific signaling
pathways, parallel to CREB-AGT axis, that may promote interstitial fibrosis and CKD. Based on these data, our central
hypothesis is that NE activates α2AR-subtypes specific-signaling pathways to induce interstitial fibrosis and their inhibition
can prevent long term sequelae of IRI. Further, α2AR activation regulates parallel pathways including, fibroblast activation
and Mφ infiltration, activation and Mφ phenotypic switching, and activates Renin-Angiotensin II Signaling (RAS) signaling
pathways to promote fibrogenesis. In specific aim 1, using genetic and pharmacological approaches, we will delineate the
functional and mechanistic role of the three α2-AR subtypes (A, B and C), and the effect of their inhibition on renal
fibrogenesis in the IRI-model. Using transcriptomic profile, we will identify overlapping versus specific pathways between
the α2AR subtypes and identify the signaling molecules that provides added protection after combinatorial inhibition. In
specific aim 2, we will dissect out the distinct role of of α2-AR subtype(s) cell-specific role (PTC vs. Mφ vs fibroblasts) in
cytokine secretion in fibroblast differentiation, Mφ behavior or Mφ switching and tubular injury. In specific aim 3, we will
identify the α2-AR subtype/s that activates CREB and AGT signaling and determine whether inhibition of AGT prevents
inflammation and fibrosis in the IRI model. The studies have high significance as they will define α2-AR as a primary
signaling molecule that regulates several of the key pathogenic molecules and processes implicated in the renal interstitial
fibrogenesis including macrophage and fibroblast activation and RAS signaling. In this regard, our studies have immediate
clinical translational potential, because α2AR inhibitors are already in clinical use in other conditions and could be adapted
rapidly to prevent the progression of fibrosis in CKD and plausibly in other organs including the liver, lung and heart.
项目摘要
急性肾损伤(AKI)被认为是进行性慢性肾脏病(CKD)的主要危险因素。然而,
AKI导致纤维化并最终导致终末期肾病(ESRD)2的机制尚未很好地定义,原因是
由于对推动纤维化形成的主要信号知之甚少,CKD的有效治疗是一项尚未满足的主要医学任务。
需要。我们的数据表明,去肾神经可以预防肾纤维化和炎症的新范例
肾纤维化模型:5/6肾切除(5/6NX)、单侧输尿管梗阻(UUO)和缺血性肾损伤(IRI)。
我们的数据表明,肾神经衍生因子去甲肾上腺素(NE)通过α2-肾上腺素能受体(α2-AR)传递信号。
在启动纤维形成和炎症中起关键作用,在损伤前或损伤后抑制它可以减少大约
在这些CKD模型中有70%。这一发现令人震惊,因为大多数实验策略都是针对单个分子或一条途径
很少能达到纤维化减少50%以上的效果。我们这项研究的总体目标是通过以下方式描述这些机制
哪个NE信号通过α2-AR诱导纤维化并确定抑制α2-AR亚型的治疗潜力
或其下游信号通路在预防IRI模型肾纤维化和炎症中的作用。我们的预赛
研究表明,去甲肾上腺素信号通过α2-AR诱导肾小管上皮细胞血管紧张素原表达
(RPTC)通过激活cAMP反应元件结合蛋白(CREB)。此外,同时抑制α2AR
A和C亚型对炎症和纤维化有额外的保护作用,表明亚型特异性信号转导被激活
与CREB-AGT轴平行的可能促进间质纤维化和CKD的通路。根据这些数据,我们的中央
假设去甲肾上腺素激活α2AR亚型特异性信号通路诱导间质纤维化及其抑制
可以预防IRI的长期后遗症。此外,α2AR的激活调节平行的通路,包括成纤维细胞的激活
和M-φ的浸润、激活和M-φ表型转换,激活肾素-血管紧张素II信号转导通路
促进纤维化形成的途径。在具体目标1中,使用遗传学和药理学方法,我们将描绘出
α2-AR三种亚型(A、B、C)的功能和机制作用及其对肾脏的抑制作用
IRI模型中的纤维化形成。使用转录图谱,我们将确定重叠和特定的途径之间
α2AR亚型和识别在组合抑制后提供额外保护的信号分子。在……里面
特定目的2,我们将剖析α2-AR亚型(S)细胞特异性角色(PTC vs Mφvs成纤维细胞)在
成纤维细胞分化、M-φ行为或M-φ转换及肾小管损伤中的细胞因子分泌在具体目标3中,我们将
确定激活CREB和AGT信号的α2-AR亚型/S,并确定抑制AGT是否可以阻止
IRI模型中的炎症和纤维化。这些研究具有很高的意义,因为他们将α2-AR定义为主要的
调节与肾间质有关的几个关键致病分子和过程的信号分子
纤维化发生包括巨噬细胞和成纤维细胞的激活以及RAS信号转导。在这方面,我们的研究已经立即
临床翻译潜力,因为α2AR抑制剂已经在其他条件下临床使用,并可以调整
快速预防慢性肾脏病的纤维化进展,其他器官,包括肝脏、肺和心脏。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
BABU Joseph PADANILAM其他文献
BABU Joseph PADANILAM的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('BABU Joseph PADANILAM', 18)}}的其他基金
Neuromodulation of long-term sequelae of ischemic acute kidney injury
缺血性急性肾损伤长期后遗症的神经调节
- 批准号:
10543829 - 财政年份:2021
- 资助金额:
$ 45.43万 - 项目类别:
Neuromodulation of long-term sequelae of ischemic acute kidney injury
缺血性急性肾损伤长期后遗症的神经调节
- 批准号:
10311243 - 财政年份:2021
- 资助金额:
$ 45.43万 - 项目类别:
Neuromodulation of long-term sequelae of ischemic acute kidney injury
缺血性急性肾损伤长期后遗症的神经调节
- 批准号:
9885585 - 财政年份:2020
- 资助金额:
$ 45.43万 - 项目类别:
Reno-protective mechanisms of EETs in acute and chronic obstructive nephropathy
EETs对急慢性梗阻性肾病的肾脏保护机制
- 批准号:
10395615 - 财政年份:2018
- 资助金额:
$ 45.43万 - 项目类别:
Reno-protective mechanisms of EETs in acute and chronic obstructive nephropathy
EETs对急慢性梗阻性肾病的肾脏保护机制
- 批准号:
10309331 - 财政年份:2018
- 资助金额:
$ 45.43万 - 项目类别:
Mechanisms of selective glycolytic inhibition in ischemic kidney proximal tubles
缺血肾近曲小管选择性糖酵解抑制机制
- 批准号:
8534448 - 财政年份:2012
- 资助金额:
$ 45.43万 - 项目类别:














{{item.name}}会员




